Condition: Resectable Pancreatic Cancer · Sponsor: Copenhagen University Hospital at Herlev
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
This description comes directly from the study's public registry record.
Julia S Johansen, MD · +45 38689241 · Julia.sidenius.johansen@regionh.dk
Sidsel C Lindgaard, MD · +45 38682984 · sidsel.christy.lindgaard@regionh.dk
Always discuss trial participation with your own doctor first.
| Aalborg Universitetshospital | Aalborg, Denmark | Recruiting |
| Aarhus Universitetshospital | Aarhus, Denmark | Recruiting |
| Copenhagen University Hospital - Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Copenhagen University Hospital - Herlev and Gentofte | Herlev, Denmark | Recruiting |
| Odense Universitetshospital | Odense, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05788744